PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 18971205-9 2009 We identified histone deacetylase (HDAC) inhibitors including vorinostat and romidepsin which are able to bypass SMN2 gene silencing by DNA methylation, while others such as valproic acid and phenylbutyrate do not, due to HDAC isoenzyme specificities. Valproic Acid 174-187 histone deacetylase 9 Homo sapiens 14-33 18971205-9 2009 We identified histone deacetylase (HDAC) inhibitors including vorinostat and romidepsin which are able to bypass SMN2 gene silencing by DNA methylation, while others such as valproic acid and phenylbutyrate do not, due to HDAC isoenzyme specificities. Valproic Acid 174-187 histone deacetylase 9 Homo sapiens 35-39 18648350-5 2008 Valproic acid (VPA), a commonly used antiepileptic agent with HDAC inhibitory activity, proved most effective when used to treat glioma cells before viral infection, but not concomitantly with viral infection. Valproic Acid 0-13 histone deacetylase 9 Homo sapiens 62-66 18611290-3 2008 Previously, we demonstrated that valproic acid (VPA), a mood stabilizer, anticonvulsant and histone deacetylase (HDAC) inhibitor, increases the expression of glial cell line-derived neurotrophic factor (GDNF) and brain-derived neurotrophic factor (BDNF) in astrocytes to protect DA neurons in midbrain neuron-glia cultures. Valproic Acid 33-46 histone deacetylase 9 Homo sapiens 92-111 18611290-3 2008 Previously, we demonstrated that valproic acid (VPA), a mood stabilizer, anticonvulsant and histone deacetylase (HDAC) inhibitor, increases the expression of glial cell line-derived neurotrophic factor (GDNF) and brain-derived neurotrophic factor (BDNF) in astrocytes to protect DA neurons in midbrain neuron-glia cultures. Valproic Acid 33-46 histone deacetylase 9 Homo sapiens 113-117 18611290-3 2008 Previously, we demonstrated that valproic acid (VPA), a mood stabilizer, anticonvulsant and histone deacetylase (HDAC) inhibitor, increases the expression of glial cell line-derived neurotrophic factor (GDNF) and brain-derived neurotrophic factor (BDNF) in astrocytes to protect DA neurons in midbrain neuron-glia cultures. Valproic Acid 48-51 histone deacetylase 9 Homo sapiens 92-111 18611290-3 2008 Previously, we demonstrated that valproic acid (VPA), a mood stabilizer, anticonvulsant and histone deacetylase (HDAC) inhibitor, increases the expression of glial cell line-derived neurotrophic factor (GDNF) and brain-derived neurotrophic factor (BDNF) in astrocytes to protect DA neurons in midbrain neuron-glia cultures. Valproic Acid 48-51 histone deacetylase 9 Homo sapiens 113-117 18266964-1 2008 The anti-epileptic drug valproic acid is also under trial as an anti-cancer agent due to its histone deacetylase (HDAC) inhibitory properties. Valproic Acid 24-37 histone deacetylase 9 Homo sapiens 93-112 18266964-1 2008 The anti-epileptic drug valproic acid is also under trial as an anti-cancer agent due to its histone deacetylase (HDAC) inhibitory properties. Valproic Acid 24-37 histone deacetylase 9 Homo sapiens 114-118 18765532-0 2008 Postradiation sensitization of the histone deacetylase inhibitor valproic acid. Valproic Acid 65-78 histone deacetylase 9 Homo sapiens 35-54 18765532-4 2008 EXPERIMENTAL DESIGN: The effects of the HDAC inhibitor valproic acid (VA) on postirradiation sensitivity in human glioma cell lines were evaluated using a clonogenic assay, exposing cells to VA up to 24 h after irradiation. Valproic Acid 55-68 histone deacetylase 9 Homo sapiens 40-44 18765532-4 2008 EXPERIMENTAL DESIGN: The effects of the HDAC inhibitor valproic acid (VA) on postirradiation sensitivity in human glioma cell lines were evaluated using a clonogenic assay, exposing cells to VA up to 24 h after irradiation. Valproic Acid 70-72 histone deacetylase 9 Homo sapiens 40-44 28189010-5 2008 Valproic acid (VPA), a commonly used antiepileptic agent with HDAC inhibitory activity, proved most effective when used to treat glioma cells before viral infection, but not concomitantly with viral infection. Valproic Acid 0-13 histone deacetylase 9 Homo sapiens 62-66 28189010-5 2008 Valproic acid (VPA), a commonly used antiepileptic agent with HDAC inhibitory activity, proved most effective when used to treat glioma cells before viral infection, but not concomitantly with viral infection. Valproic Acid 15-18 histone deacetylase 9 Homo sapiens 62-66 18648350-5 2008 Valproic acid (VPA), a commonly used antiepileptic agent with HDAC inhibitory activity, proved most effective when used to treat glioma cells before viral infection, but not concomitantly with viral infection. Valproic Acid 15-18 histone deacetylase 9 Homo sapiens 62-66 17186358-2 2007 HDAC inhibitors [trichostatin A (TSA), suberoylanilide hydroxamic acid (SAHA) and valproic acid (VPA)], inhibited proliferation of MCF-7 breast cancer cells and, in combination with tamoxifen inhibited proliferation better than with either agent alone. Valproic Acid 82-95 histone deacetylase 9 Homo sapiens 0-4 18550052-0 2008 Clinically relevant concentrations of valproic acid modulate melatonin MT(1) receptor, HDAC and MeCP2 mRNA expression in C6 glioma cells. Valproic Acid 38-51 histone deacetylase 9 Homo sapiens 87-91 18570928-5 2008 In this study, we investigated the ability of the HDAC inhibitor valproic acid (VPA) to activate Notch1 signaling and inhibit proliferation in SCLC cells. Valproic Acid 65-78 histone deacetylase 9 Homo sapiens 50-54 18570928-5 2008 In this study, we investigated the ability of the HDAC inhibitor valproic acid (VPA) to activate Notch1 signaling and inhibit proliferation in SCLC cells. Valproic Acid 80-83 histone deacetylase 9 Homo sapiens 50-54 18568017-3 2008 In particular, valproic acid (VPA), an HDAC inhibitor, improves reprogramming efficiency by more than 100-fold, using Oct4-GFP as a reporter. Valproic Acid 15-28 histone deacetylase 9 Homo sapiens 39-43 18568017-3 2008 In particular, valproic acid (VPA), an HDAC inhibitor, improves reprogramming efficiency by more than 100-fold, using Oct4-GFP as a reporter. Valproic Acid 30-33 histone deacetylase 9 Homo sapiens 39-43 18294844-0 2008 New sulfurated derivatives of valproic acid with enhanced histone deacetylase inhibitory activity. Valproic Acid 30-43 histone deacetylase 9 Homo sapiens 58-77 18294844-1 2008 One dithiolthione and two new methanethiosulfonate derivatives of valproic acid (VPA) were synthesized and tested in vitro as histone deacetylase (HDAC) inhibitors. Valproic Acid 66-79 histone deacetylase 9 Homo sapiens 126-145 18294844-1 2008 One dithiolthione and two new methanethiosulfonate derivatives of valproic acid (VPA) were synthesized and tested in vitro as histone deacetylase (HDAC) inhibitors. Valproic Acid 66-79 histone deacetylase 9 Homo sapiens 147-151 18294844-1 2008 One dithiolthione and two new methanethiosulfonate derivatives of valproic acid (VPA) were synthesized and tested in vitro as histone deacetylase (HDAC) inhibitors. Valproic Acid 81-84 histone deacetylase 9 Homo sapiens 126-145 18294844-1 2008 One dithiolthione and two new methanethiosulfonate derivatives of valproic acid (VPA) were synthesized and tested in vitro as histone deacetylase (HDAC) inhibitors. Valproic Acid 81-84 histone deacetylase 9 Homo sapiens 147-151 18294844-2 2008 The new molecules, as well as their sulfurated moieties, exhibited a much stronger inhibition of HDAC enzymatic and antiproliferative activities and histone hyperacetylation than VPA. Valproic Acid 179-182 histone deacetylase 9 Homo sapiens 97-101 18322101-2 2008 Lithium, a glycogen synthase kinase-3 (GSK-3) inhibitor, and VPA, a histone deacetylase (HDAC) inhibitor, have neuroprotective effects. Valproic Acid 61-64 histone deacetylase 9 Homo sapiens 68-87 18322101-2 2008 Lithium, a glycogen synthase kinase-3 (GSK-3) inhibitor, and VPA, a histone deacetylase (HDAC) inhibitor, have neuroprotective effects. Valproic Acid 61-64 histone deacetylase 9 Homo sapiens 89-93 17982680-4 2007 The HDAC inhibitors valproic acid, PXD101, trichostatin A and sodium butyrate inhibited leukaemic and clonogenic cell proliferation and increased apoptosis in a dose-dependent manner when tested at high concentrations. Valproic Acid 20-33 histone deacetylase 9 Homo sapiens 4-8 17186358-2 2007 HDAC inhibitors [trichostatin A (TSA), suberoylanilide hydroxamic acid (SAHA) and valproic acid (VPA)], inhibited proliferation of MCF-7 breast cancer cells and, in combination with tamoxifen inhibited proliferation better than with either agent alone. Valproic Acid 97-100 histone deacetylase 9 Homo sapiens 0-4 17186358-3 2007 VPA, an anti-convulsant drug with HDAC inhibitory activity, enhanced tamoxifen action at doses within the concentration range used for anti-convulsive therapy. Valproic Acid 0-3 histone deacetylase 9 Homo sapiens 34-38 17709382-1 2007 Histone deacetylase (HDAC) inhibitors such as trichostatin A and valproic acid modulate transcription of many genes by inhibiting the activities of HDACs, resulting in the remodeling of chromatin. Valproic Acid 65-78 histone deacetylase 9 Homo sapiens 0-19 17709382-1 2007 Histone deacetylase (HDAC) inhibitors such as trichostatin A and valproic acid modulate transcription of many genes by inhibiting the activities of HDACs, resulting in the remodeling of chromatin. Valproic Acid 65-78 histone deacetylase 9 Homo sapiens 21-25 17579623-2 2007 This study was designed to determine the safety and maximum tolerated dose (MTD) of valproic acid (VPA) as an HDAC inhibitor in cancer patients. Valproic Acid 84-97 histone deacetylase 9 Homo sapiens 110-114 17566732-0 2007 Induction of GRP78 by valproic acid is dependent upon histone deacetylase inhibition. Valproic Acid 22-35 histone deacetylase 9 Homo sapiens 54-73 17566732-2 2007 The molecular mechanism that underlies its clinical efficacy remains controversial and is complicated by the broad range of intracellular effects of valproic acid, including its ability to inhibit histone deacetylase (HDAC) and induce protein chaperone expression. Valproic Acid 149-162 histone deacetylase 9 Homo sapiens 197-216 17566732-2 2007 The molecular mechanism that underlies its clinical efficacy remains controversial and is complicated by the broad range of intracellular effects of valproic acid, including its ability to inhibit histone deacetylase (HDAC) and induce protein chaperone expression. Valproic Acid 149-162 histone deacetylase 9 Homo sapiens 218-222 17671692-0 2007 The histone deacetylase inhibitors suberoylanilide hydroxamic (Vorinostat) and valproic acid induce irreversible and MDR1-independent resistance in human colon cancer cells. Valproic Acid 79-92 histone deacetylase 9 Homo sapiens 4-23 17671692-1 2007 Histone deacetylase (HDAC) inhibitors such as suberoylanilide hydroxamic acid (SAHA, Vorinostat), valproic acid (VPA), and FK228 are members of a relatively novel class of small molecular weight chemicals that have high antineoplastic activity. Valproic Acid 98-111 histone deacetylase 9 Homo sapiens 0-19 17671692-1 2007 Histone deacetylase (HDAC) inhibitors such as suberoylanilide hydroxamic acid (SAHA, Vorinostat), valproic acid (VPA), and FK228 are members of a relatively novel class of small molecular weight chemicals that have high antineoplastic activity. Valproic Acid 98-111 histone deacetylase 9 Homo sapiens 21-25 17671692-1 2007 Histone deacetylase (HDAC) inhibitors such as suberoylanilide hydroxamic acid (SAHA, Vorinostat), valproic acid (VPA), and FK228 are members of a relatively novel class of small molecular weight chemicals that have high antineoplastic activity. Valproic Acid 113-116 histone deacetylase 9 Homo sapiens 0-19 17671692-1 2007 Histone deacetylase (HDAC) inhibitors such as suberoylanilide hydroxamic acid (SAHA, Vorinostat), valproic acid (VPA), and FK228 are members of a relatively novel class of small molecular weight chemicals that have high antineoplastic activity. Valproic Acid 113-116 histone deacetylase 9 Homo sapiens 21-25 17671692-7 2007 The SAHA- and VPA-induced resistant sublines were also stably cross-resistant to VPA and SAHA, respectively, but retained sensitivity against non-HDAC inhibitor-type anticancer agents. Valproic Acid 14-17 histone deacetylase 9 Homo sapiens 146-150 17579623-2 2007 This study was designed to determine the safety and maximum tolerated dose (MTD) of valproic acid (VPA) as an HDAC inhibitor in cancer patients. Valproic Acid 99-102 histone deacetylase 9 Homo sapiens 110-114 17537967-4 2007 We show here that the antiepileptic drug valproic acid (VPA) potently blocked seizure-induced neurogenesis, an effect that appeared to be mainly mediated by inhibiting histone deacetylases (HDAC) and normalizing HDAC-dependent gene expression within the epileptic dentate area. Valproic Acid 41-54 histone deacetylase 9 Homo sapiens 168-188 17371805-3 2007 We found that post-pMCAO injections with HDAC inhibitors, valproic acid (VPA), sodium butyrate (SB), or trichostatin A (TSA), decreased brain infarct volume. Valproic Acid 58-71 histone deacetylase 9 Homo sapiens 41-45 17371805-3 2007 We found that post-pMCAO injections with HDAC inhibitors, valproic acid (VPA), sodium butyrate (SB), or trichostatin A (TSA), decreased brain infarct volume. Valproic Acid 73-76 histone deacetylase 9 Homo sapiens 41-45 17371805-11 2007 Given that there is no effective treatment for stroke, HDAC inhibitors, such as VPA, SB, and TSA, should be evaluated for their potential use for clinical trials in stroke patients. Valproic Acid 80-83 histone deacetylase 9 Homo sapiens 55-59 17537967-4 2007 We show here that the antiepileptic drug valproic acid (VPA) potently blocked seizure-induced neurogenesis, an effect that appeared to be mainly mediated by inhibiting histone deacetylases (HDAC) and normalizing HDAC-dependent gene expression within the epileptic dentate area. Valproic Acid 41-54 histone deacetylase 9 Homo sapiens 190-194 17537967-4 2007 We show here that the antiepileptic drug valproic acid (VPA) potently blocked seizure-induced neurogenesis, an effect that appeared to be mainly mediated by inhibiting histone deacetylases (HDAC) and normalizing HDAC-dependent gene expression within the epileptic dentate area. Valproic Acid 41-54 histone deacetylase 9 Homo sapiens 212-216 17537967-4 2007 We show here that the antiepileptic drug valproic acid (VPA) potently blocked seizure-induced neurogenesis, an effect that appeared to be mainly mediated by inhibiting histone deacetylases (HDAC) and normalizing HDAC-dependent gene expression within the epileptic dentate area. Valproic Acid 56-59 histone deacetylase 9 Homo sapiens 168-188 17537967-4 2007 We show here that the antiepileptic drug valproic acid (VPA) potently blocked seizure-induced neurogenesis, an effect that appeared to be mainly mediated by inhibiting histone deacetylases (HDAC) and normalizing HDAC-dependent gene expression within the epileptic dentate area. Valproic Acid 56-59 histone deacetylase 9 Homo sapiens 190-194 17537967-4 2007 We show here that the antiepileptic drug valproic acid (VPA) potently blocked seizure-induced neurogenesis, an effect that appeared to be mainly mediated by inhibiting histone deacetylases (HDAC) and normalizing HDAC-dependent gene expression within the epileptic dentate area. Valproic Acid 56-59 histone deacetylase 9 Homo sapiens 212-216 16001982-0 2005 Histone acetylation and histone deacetylase activity of magnesium valproate in tumor and peripheral blood of patients with cervical cancer. Valproic Acid 56-75 histone deacetylase 9 Homo sapiens 24-43 16323176-0 2006 The histone deacetylase (HDAC) inhibitor valproic acid as monotherapy or in combination with all-trans retinoic acid in patients with acute myeloid leukemia. Valproic Acid 41-54 histone deacetylase 9 Homo sapiens 4-23 16323176-0 2006 The histone deacetylase (HDAC) inhibitor valproic acid as monotherapy or in combination with all-trans retinoic acid in patients with acute myeloid leukemia. Valproic Acid 41-54 histone deacetylase 9 Homo sapiens 25-29 16323176-1 2006 BACKGROUND: Valproic acid (VPA) inhibits histone deacetylase activity and, synergizing with all-trans retinoic acid (ATRA), achieves differentiation induction of myeloid blast cells in vitro. Valproic Acid 12-25 histone deacetylase 9 Homo sapiens 41-60 16323176-1 2006 BACKGROUND: Valproic acid (VPA) inhibits histone deacetylase activity and, synergizing with all-trans retinoic acid (ATRA), achieves differentiation induction of myeloid blast cells in vitro. Valproic Acid 27-30 histone deacetylase 9 Homo sapiens 41-60 16123451-0 2005 Increased replication of human cytomegalovirus in retinal pigment epithelial cells by valproic acid depends on histone deacetylase inhibition. Valproic Acid 86-99 histone deacetylase 9 Homo sapiens 111-130 17183730-15 2006 CONCLUSIONS: Hydralazine and magnesium valproate produce DNA demethylation, HDAC inhibition, and gene reactivation in primary tumors. Valproic Acid 29-48 histone deacetylase 9 Homo sapiens 76-80 17088416-0 2006 Valproic acid, a histone deacetylase inhibitor, enhances sensitivity to doxorubicin in anaplastic thyroid cancer cells. Valproic Acid 0-13 histone deacetylase 9 Homo sapiens 17-36 17088416-5 2006 Using two ATC cell lines (CAL-62 and ARO), we show here that valproic acid (VPA), a clinically available HDAC inhibitor, enhances the activity of doxorubicin, whose anti-tumor properties involve binding to DNA and inhibiting topoisomerase II. Valproic Acid 61-74 histone deacetylase 9 Homo sapiens 105-109 17088416-5 2006 Using two ATC cell lines (CAL-62 and ARO), we show here that valproic acid (VPA), a clinically available HDAC inhibitor, enhances the activity of doxorubicin, whose anti-tumor properties involve binding to DNA and inhibiting topoisomerase II. Valproic Acid 76-79 histone deacetylase 9 Homo sapiens 105-109 16583461-2 2006 Recently, we found 2 histone deacetylase inhibitors (HDAC-I), valproic acid and ITF2357, exhibiting inherent therapeutic activity against HCC. Valproic Acid 62-75 histone deacetylase 9 Homo sapiens 53-57 16193500-2 2005 Among HDAC inhibitors, Trichostatin A (TSA) and Valproic Acid (VPA) prevent the tumorigenesis in rodent and human models. Valproic Acid 48-61 histone deacetylase 9 Homo sapiens 6-10 16193500-2 2005 Among HDAC inhibitors, Trichostatin A (TSA) and Valproic Acid (VPA) prevent the tumorigenesis in rodent and human models. Valproic Acid 63-66 histone deacetylase 9 Homo sapiens 6-10 15915507-7 2005 RESULTS: Flow cytometric detection of acetylation status can successfully detect modifications induced by HDAC inhibitor treatment in vivo as demonstrated by analysis of various blood samples from patients treated with valproic acid. Valproic Acid 219-232 histone deacetylase 9 Homo sapiens 106-110 15242819-1 2004 Valproic acid (2-propylpentanoic acid, VPA), an effective inhibitor of histone deacetylases (HDAC) is used for the treatment of epilepsia. Valproic Acid 0-13 histone deacetylase 9 Homo sapiens 71-91 15242819-1 2004 Valproic acid (2-propylpentanoic acid, VPA), an effective inhibitor of histone deacetylases (HDAC) is used for the treatment of epilepsia. Valproic Acid 0-13 histone deacetylase 9 Homo sapiens 93-97 15242819-1 2004 Valproic acid (2-propylpentanoic acid, VPA), an effective inhibitor of histone deacetylases (HDAC) is used for the treatment of epilepsia. Valproic Acid 15-37 histone deacetylase 9 Homo sapiens 71-91 15242819-1 2004 Valproic acid (2-propylpentanoic acid, VPA), an effective inhibitor of histone deacetylases (HDAC) is used for the treatment of epilepsia. Valproic Acid 15-37 histone deacetylase 9 Homo sapiens 93-97 15242819-1 2004 Valproic acid (2-propylpentanoic acid, VPA), an effective inhibitor of histone deacetylases (HDAC) is used for the treatment of epilepsia. Valproic Acid 39-42 histone deacetylase 9 Homo sapiens 71-91 15242819-1 2004 Valproic acid (2-propylpentanoic acid, VPA), an effective inhibitor of histone deacetylases (HDAC) is used for the treatment of epilepsia. Valproic Acid 39-42 histone deacetylase 9 Homo sapiens 93-97 14985358-0 2004 Inhibition of histone deacetylase activity by valproic acid blocks adipogenesis. Valproic Acid 46-59 histone deacetylase 9 Homo sapiens 14-33 15107823-2 2004 Inhibition of histone deacetylase (HDAC) activity with trichostatin A (TSA) or valproic acid (VPA) at concentrations that do not affect morphology, motility, chemotaxis or proliferation, strongly inhibits invasion and results in the re-expression of a significant proportion of those genes that are downregulated in the v-Fos-transformed cells. Valproic Acid 79-92 histone deacetylase 9 Homo sapiens 14-33 15107823-2 2004 Inhibition of histone deacetylase (HDAC) activity with trichostatin A (TSA) or valproic acid (VPA) at concentrations that do not affect morphology, motility, chemotaxis or proliferation, strongly inhibits invasion and results in the re-expression of a significant proportion of those genes that are downregulated in the v-Fos-transformed cells. Valproic Acid 79-92 histone deacetylase 9 Homo sapiens 35-39 15107823-2 2004 Inhibition of histone deacetylase (HDAC) activity with trichostatin A (TSA) or valproic acid (VPA) at concentrations that do not affect morphology, motility, chemotaxis or proliferation, strongly inhibits invasion and results in the re-expression of a significant proportion of those genes that are downregulated in the v-Fos-transformed cells. Valproic Acid 94-97 histone deacetylase 9 Homo sapiens 14-33 15107823-2 2004 Inhibition of histone deacetylase (HDAC) activity with trichostatin A (TSA) or valproic acid (VPA) at concentrations that do not affect morphology, motility, chemotaxis or proliferation, strongly inhibits invasion and results in the re-expression of a significant proportion of those genes that are downregulated in the v-Fos-transformed cells. Valproic Acid 94-97 histone deacetylase 9 Homo sapiens 35-39 15166525-2 2004 OBJECTIVES: To test the ability of valproic acid (VPA), an inhibitor of HDAC in clinical use, to induce expression of HIV from resting CD4 T cells. Valproic Acid 35-48 histone deacetylase 9 Homo sapiens 72-76 15166525-2 2004 OBJECTIVES: To test the ability of valproic acid (VPA), an inhibitor of HDAC in clinical use, to induce expression of HIV from resting CD4 T cells. Valproic Acid 50-53 histone deacetylase 9 Homo sapiens 72-76 14985358-2 2004 We show that the mood stabilizing drug valproic acid (VPA; 0.5-2 mm) inhibits mouse 3T3 L1 and human preadipocyte differentiation, likely through its histone deacetylase (HDAC) inhibitory properties. Valproic Acid 39-52 histone deacetylase 9 Homo sapiens 150-169 14985358-2 2004 We show that the mood stabilizing drug valproic acid (VPA; 0.5-2 mm) inhibits mouse 3T3 L1 and human preadipocyte differentiation, likely through its histone deacetylase (HDAC) inhibitory properties. Valproic Acid 39-52 histone deacetylase 9 Homo sapiens 171-175 14985358-2 2004 We show that the mood stabilizing drug valproic acid (VPA; 0.5-2 mm) inhibits mouse 3T3 L1 and human preadipocyte differentiation, likely through its histone deacetylase (HDAC) inhibitory properties. Valproic Acid 54-57 histone deacetylase 9 Homo sapiens 150-169 14985358-2 2004 We show that the mood stabilizing drug valproic acid (VPA; 0.5-2 mm) inhibits mouse 3T3 L1 and human preadipocyte differentiation, likely through its histone deacetylase (HDAC) inhibitory properties. Valproic Acid 54-57 histone deacetylase 9 Homo sapiens 171-175 15026552-4 2004 We found that the antitumor agents known as histone deacetylase (HDAC) inhibitors (phenylbutyrate, trichostatin A, and valproic acid) could suppress cutaneous radiation syndrome. Valproic Acid 119-132 histone deacetylase 9 Homo sapiens 44-63 15033455-5 2004 We therefore set out to investigate whether the HDAC inhibitor valproic acid also impairs angiogenesis. Valproic Acid 63-76 histone deacetylase 9 Homo sapiens 48-52 15033455-9 2004 These results suggest that the HDAC inhibitor valproic acid could become a valuable new addition in the attempt to develop alternative therapeutic approaches in the treatment of colon carcinomas. Valproic Acid 46-59 histone deacetylase 9 Homo sapiens 31-35 15026552-4 2004 We found that the antitumor agents known as histone deacetylase (HDAC) inhibitors (phenylbutyrate, trichostatin A, and valproic acid) could suppress cutaneous radiation syndrome. Valproic Acid 119-132 histone deacetylase 9 Homo sapiens 65-69 12015604-4 2002 The action of valproic acid has been linked to both inositol depletion and to inhibition of histone deacetylase (HDAC). Valproic Acid 14-27 histone deacetylase 9 Homo sapiens 92-111 12015604-4 2002 The action of valproic acid has been linked to both inositol depletion and to inhibition of histone deacetylase (HDAC). Valproic Acid 14-27 histone deacetylase 9 Homo sapiens 113-117 33031880-0 2021 Biocompatible sulfated valproic acid-coupled polysaccharide-based nanocarriers with HDAC inhibitory activity. Valproic Acid 23-36 histone deacetylase 9 Homo sapiens 84-88 34944565-6 2021 Herein, we present evidence that a combined treatment of 2-DG analogs and modulation of histone deacetylases (HDAC) activity via HDAC inhibitors (sodium butyrate and sodium valproate) exerts synergistic cytotoxic effects in glioblastoma U-87 and U-251 cells and represents a promising therapeutic strategy. Valproic Acid 166-182 histone deacetylase 9 Homo sapiens 88-108 34935488-5 2021 In follow-up experiments, it was verified that sodium valproate (SVA), as a HDAC9 inhibitor, can indeed antagonize the inflammatory damage of vascular endothelial cells, as well as SB203580, which is a P38 MAPK inhibitor. Valproic Acid 47-63 histone deacetylase 9 Homo sapiens 76-81 34935488-5 2021 In follow-up experiments, it was verified that sodium valproate (SVA), as a HDAC9 inhibitor, can indeed antagonize the inflammatory damage of vascular endothelial cells, as well as SB203580, which is a P38 MAPK inhibitor. Valproic Acid 65-68 histone deacetylase 9 Homo sapiens 76-81 34944565-6 2021 Herein, we present evidence that a combined treatment of 2-DG analogs and modulation of histone deacetylases (HDAC) activity via HDAC inhibitors (sodium butyrate and sodium valproate) exerts synergistic cytotoxic effects in glioblastoma U-87 and U-251 cells and represents a promising therapeutic strategy. Valproic Acid 166-182 histone deacetylase 9 Homo sapiens 110-114 34944565-6 2021 Herein, we present evidence that a combined treatment of 2-DG analogs and modulation of histone deacetylases (HDAC) activity via HDAC inhibitors (sodium butyrate and sodium valproate) exerts synergistic cytotoxic effects in glioblastoma U-87 and U-251 cells and represents a promising therapeutic strategy. Valproic Acid 166-182 histone deacetylase 9 Homo sapiens 129-133 35565292-0 2022 HDAC Inhibition with Valproate Improves Direct Cytotoxicity of Monocytes against Mesothelioma Tumor Cells. Valproic Acid 21-30 histone deacetylase 9 Homo sapiens 0-4 34374891-0 2021 Effect of valproic acid on miRNAs affecting histone deacetylase in a model of anaplastic thyroid cancer. Valproic Acid 10-23 histone deacetylase 9 Homo sapiens 44-63 34374891-7 2021 Also, the effect of VPA on miRNAs affecting histone deacetylase was determined by Quantitative RT-PCR. Valproic Acid 20-23 histone deacetylase 9 Homo sapiens 44-63 35433850-5 2022 These phenotypes could be reverted by treatment with HDAC inhibitors, including sodium valproate and small molecules inhibitors. Valproic Acid 80-96 histone deacetylase 9 Homo sapiens 53-57 33369712-11 2021 The effects of ASIV on reducing CCL2 production, restoring acetylated p65 levels and preventing p65 nuclear translocation were mimicked by valproate, an HDAC inhibitor, in astrocytes subjected to oxygen-glucose deprivation. Valproic Acid 139-148 histone deacetylase 9 Homo sapiens 153-157 32591993-6 2020 Importantly, HDAC inhibitor treatment with SAHA or valproic acid induced cell cycle arrest and strongly increased PD-L1 expression of the tumor cells. Valproic Acid 51-64 histone deacetylase 9 Homo sapiens 13-17 31898801-1 2020 Valproic acid (VPA), a histone deacetylase (HDAC) inhibitor is a widely used anticonvulsant drug. Valproic Acid 0-13 histone deacetylase 9 Homo sapiens 23-42 31898801-1 2020 Valproic acid (VPA), a histone deacetylase (HDAC) inhibitor is a widely used anticonvulsant drug. Valproic Acid 0-13 histone deacetylase 9 Homo sapiens 44-48 31898801-1 2020 Valproic acid (VPA), a histone deacetylase (HDAC) inhibitor is a widely used anticonvulsant drug. Valproic Acid 15-18 histone deacetylase 9 Homo sapiens 23-42 31898801-1 2020 Valproic acid (VPA), a histone deacetylase (HDAC) inhibitor is a widely used anticonvulsant drug. Valproic Acid 15-18 histone deacetylase 9 Homo sapiens 44-48 31898801-9 2020 In conclusion, the pan-HDAC inhibitor VPA described for expansion of hematopoietic stem cells and very small embryonic like stem cells cannot be successfully employed for differentiation of endothelial lineage committed ECFC into functional endothelial cells. Valproic Acid 38-41 histone deacetylase 9 Homo sapiens 23-27 32378621-4 2020 Methods : We made cancer sphere from HepG2 cells, and we added Histone deacetylase (HDAC) inhibitor, valproic acid to cancer sphere. Valproic Acid 101-114 histone deacetylase 9 Homo sapiens 63-82 32378621-4 2020 Methods : We made cancer sphere from HepG2 cells, and we added Histone deacetylase (HDAC) inhibitor, valproic acid to cancer sphere. Valproic Acid 101-114 histone deacetylase 9 Homo sapiens 84-88 31010254-0 2019 Influence of the HDAC Inhibitor Valproic Acid on the Growth and Proliferation of Temsirolimus-Resistant Prostate Cancer Cells In Vitro. Valproic Acid 32-45 histone deacetylase 9 Homo sapiens 17-21 31010254-3 2019 We determined whether epigenetic modulation by the histone deacetylase (HDAC) inhibitor, valproic acid (VPA), may counteract non-responsiveness to the mTOR inhibitor, temsirolimus, in prostate cancer (PCa) cells. Valproic Acid 89-102 histone deacetylase 9 Homo sapiens 51-70 31010254-3 2019 We determined whether epigenetic modulation by the histone deacetylase (HDAC) inhibitor, valproic acid (VPA), may counteract non-responsiveness to the mTOR inhibitor, temsirolimus, in prostate cancer (PCa) cells. Valproic Acid 89-102 histone deacetylase 9 Homo sapiens 72-76 31010254-3 2019 We determined whether epigenetic modulation by the histone deacetylase (HDAC) inhibitor, valproic acid (VPA), may counteract non-responsiveness to the mTOR inhibitor, temsirolimus, in prostate cancer (PCa) cells. Valproic Acid 104-107 histone deacetylase 9 Homo sapiens 51-70 31010254-3 2019 We determined whether epigenetic modulation by the histone deacetylase (HDAC) inhibitor, valproic acid (VPA), may counteract non-responsiveness to the mTOR inhibitor, temsirolimus, in prostate cancer (PCa) cells. Valproic Acid 104-107 histone deacetylase 9 Homo sapiens 72-76 30183517-8 2019 The lethality of [neratinib + palbociclib] was modestly enhanced by the PDE5 inhibitor sildenafil and strongly enhanced by the HDAC inhibitor sodium valproate. Valproic Acid 142-158 histone deacetylase 9 Homo sapiens 127-131 28967098-6 2018 VPA is known to affect gene expression through several mechanisms, including the modulation of intracellular kinase pathways and transcription factors, as well as the inhibition of histone deacetylase (HDAC) activity. Valproic Acid 0-3 histone deacetylase 9 Homo sapiens 181-200 30107147-3 2018 In this study, we investigated the effect of HDAC inhibition on EMT in HCC cells by using trichostatin A (TSA) and valproic acid (VPA). Valproic Acid 115-128 histone deacetylase 9 Homo sapiens 45-49 30107147-3 2018 In this study, we investigated the effect of HDAC inhibition on EMT in HCC cells by using trichostatin A (TSA) and valproic acid (VPA). Valproic Acid 130-133 histone deacetylase 9 Homo sapiens 45-49 28967098-6 2018 VPA is known to affect gene expression through several mechanisms, including the modulation of intracellular kinase pathways and transcription factors, as well as the inhibition of histone deacetylase (HDAC) activity. Valproic Acid 0-3 histone deacetylase 9 Homo sapiens 202-206 29135083-0 2018 Comparison of the anticancer properties of a novel valproic acid prodrug to leading histone deacetylase inhibitors. Valproic Acid 51-64 histone deacetylase 9 Homo sapiens 84-103 28550492-9 2018 HCC cells exposed to the histone deacetylase (HDAC) inhibitor sodium valproate showed downregulation of miR-889. Valproic Acid 62-78 histone deacetylase 9 Homo sapiens 25-44 28550492-9 2018 HCC cells exposed to the histone deacetylase (HDAC) inhibitor sodium valproate showed downregulation of miR-889. Valproic Acid 62-78 histone deacetylase 9 Homo sapiens 46-50 30050079-7 2018 Furthermore, co-inhibition of mTORC1 and HDAC with rapamycin and valproic acid, but neither alone, reproducibly promoted ESR1 expression in TNBC cells. Valproic Acid 65-78 histone deacetylase 9 Homo sapiens 41-45 29135083-1 2018 The HDAC inhibitory activity of valproic acid (VPA) has led to on-going evaluation of it as an anticancer agent. Valproic Acid 32-45 histone deacetylase 9 Homo sapiens 4-8 29135083-1 2018 The HDAC inhibitory activity of valproic acid (VPA) has led to on-going evaluation of it as an anticancer agent. Valproic Acid 47-50 histone deacetylase 9 Homo sapiens 4-8 29135083-2 2018 The histone deacetylase (HDAC) inhibitor AN446, a prodrug of VPA, releases the acid upon metabolic degradation. Valproic Acid 61-64 histone deacetylase 9 Homo sapiens 4-23 29135083-2 2018 The histone deacetylase (HDAC) inhibitor AN446, a prodrug of VPA, releases the acid upon metabolic degradation. Valproic Acid 61-64 histone deacetylase 9 Homo sapiens 25-29 28542253-8 2017 These results demonstrate that sodium valproate causes increased histone H3 acetylation indicative of HDAC inhibition, which is inversely correlated with a reduction in cell viability. Valproic Acid 31-47 histone deacetylase 9 Homo sapiens 102-106 29247141-3 2018 The antiepileptic drug sodium valproate (SVA) is a nonspecific inhibitor of HDAC9. Valproic Acid 23-39 histone deacetylase 9 Homo sapiens 76-81 29247141-3 2018 The antiepileptic drug sodium valproate (SVA) is a nonspecific inhibitor of HDAC9. Valproic Acid 41-44 histone deacetylase 9 Homo sapiens 76-81 28445158-0 2017 The HDAC inhibitor valproate induces a bivalent status of the CD20 promoter in CLL patients suggesting distinct epigenetic regulation of CD20 expression in CLL in vivo. Valproic Acid 19-28 histone deacetylase 9 Homo sapiens 4-8 28445158-4 2017 Valproate treatment resulted in expected global activating histone modifications suggesting HDAC inhibitory effects. Valproic Acid 0-9 histone deacetylase 9 Homo sapiens 92-96 27411759-0 2016 Anti-fibrotic effects of valproic acid: role of HDAC inhibition and associated mechanisms. Valproic Acid 25-38 histone deacetylase 9 Homo sapiens 48-52 27884140-5 2016 Due to its histone deacetylase (HDAC) inhibiting activity and its safe use as a chronic therapy for epileptic disorders, valproic acid (VPA) has been considered a good candidate for anticancer therapy. Valproic Acid 121-134 histone deacetylase 9 Homo sapiens 11-30 27884140-5 2016 Due to its histone deacetylase (HDAC) inhibiting activity and its safe use as a chronic therapy for epileptic disorders, valproic acid (VPA) has been considered a good candidate for anticancer therapy. Valproic Acid 121-134 histone deacetylase 9 Homo sapiens 32-36 27470189-5 2016 Cell death with DNA breaks in the nucleus was greater using combined regimens of PAM and HDAC inhibitors such as trichostatin A (TSA) and valproic acid (VPA) than a single PAM treatment and was accompanied by the activation of poly (ADP-ribose) polymerase-1 (PARP-1), depletion of ATP, and elevations in intracellular calcium levels. Valproic Acid 138-151 histone deacetylase 9 Homo sapiens 89-93 27470189-5 2016 Cell death with DNA breaks in the nucleus was greater using combined regimens of PAM and HDAC inhibitors such as trichostatin A (TSA) and valproic acid (VPA) than a single PAM treatment and was accompanied by the activation of poly (ADP-ribose) polymerase-1 (PARP-1), depletion of ATP, and elevations in intracellular calcium levels. Valproic Acid 153-156 histone deacetylase 9 Homo sapiens 89-93 27411759-4 2016 Valproic acid is a first-line anti-epileptic drug and a proven HDAC inhibitor. Valproic Acid 0-13 histone deacetylase 9 Homo sapiens 63-67 26318673-3 2015 Here, we showed that histone deacetylase (HDAC) inhibitors, such as trichostatin A and valproic acid, restored peripheral and systemic morphine analgesia in neuropathic pain. Valproic Acid 87-100 histone deacetylase 9 Homo sapiens 21-40 27038166-7 2016 Overall prostate cancer risk decreased in a dose-dependent manner by cumulative amount, duration and yearly dosage (intensity) of HDAC inhibitors valproic acid and carbamazepine. Valproic Acid 146-159 histone deacetylase 9 Homo sapiens 130-134 26827693-3 2016 Since the first HDAC inhibitor, valproic acid, was investigated as a potential antitumor agent, there have been a number of other HDAC inhibitors developed to improve efficacy and safety. Valproic Acid 32-45 histone deacetylase 9 Homo sapiens 16-20 26482599-1 2015 BACKGROUND AND PURPOSE: There is mounting evidence that histone deacetylase (HDAC) inhibitors, e.g. valproic acid (VPA), synergize with radiation to improve outcomes in several cancers. Valproic Acid 100-113 histone deacetylase 9 Homo sapiens 56-75 26482599-1 2015 BACKGROUND AND PURPOSE: There is mounting evidence that histone deacetylase (HDAC) inhibitors, e.g. valproic acid (VPA), synergize with radiation to improve outcomes in several cancers. Valproic Acid 100-113 histone deacetylase 9 Homo sapiens 77-81 26482599-1 2015 BACKGROUND AND PURPOSE: There is mounting evidence that histone deacetylase (HDAC) inhibitors, e.g. valproic acid (VPA), synergize with radiation to improve outcomes in several cancers. Valproic Acid 115-118 histone deacetylase 9 Homo sapiens 56-75 26482599-1 2015 BACKGROUND AND PURPOSE: There is mounting evidence that histone deacetylase (HDAC) inhibitors, e.g. valproic acid (VPA), synergize with radiation to improve outcomes in several cancers. Valproic Acid 115-118 histone deacetylase 9 Homo sapiens 77-81 26980768-9 2016 The influence of class I HDACs on DSB repair by homologous recombination and the possible clinical implication on malignant melanoma therapy with temozolomide and other alkylating drugs suggests a combination approach where class I HDAC inhibitors such as valproic acid or MS-275 (entinostat) appear to counteract HDAC- and RAD51/FANCD2-mediated melanoma cell resistance. Valproic Acid 256-269 histone deacetylase 9 Homo sapiens 232-236 26822725-1 2016 Valproic acid (VPA) and suberoylanilide hydroxamic acid (SAHA) are both HDAC inhibitors (HDACi). Valproic Acid 0-13 histone deacetylase 9 Homo sapiens 72-76 26822725-1 2016 Valproic acid (VPA) and suberoylanilide hydroxamic acid (SAHA) are both HDAC inhibitors (HDACi). Valproic Acid 15-18 histone deacetylase 9 Homo sapiens 72-76 26822725-6 2016 This study revealed the differential impacts of VPA and SAHA on proteome/acetylome in AML cells, deepening our understanding of HDAC inhibitor mediated AML therapeutics. Valproic Acid 48-51 histone deacetylase 9 Homo sapiens 128-132 26517778-1 2016 BACKGROUND: Treatment with histone deacetylase (HDAC) inhibitors, such as valproic acid, increases survival in animal models of trauma and sepsis. Valproic Acid 74-87 histone deacetylase 9 Homo sapiens 27-46 26517778-1 2016 BACKGROUND: Treatment with histone deacetylase (HDAC) inhibitors, such as valproic acid, increases survival in animal models of trauma and sepsis. Valproic Acid 74-87 histone deacetylase 9 Homo sapiens 48-52 26517778-2 2016 Valproic acid is a pan-inhibitor that blocks most of the known HDAC isoforms. Valproic Acid 0-13 histone deacetylase 9 Homo sapiens 63-67 26108793-9 2015 When oocytes were exposed to the HDAC inhibitor valproic acid, results indicated that HDAC regulated transcriptional activity in the nucleoplasm, but not in the nucleolus. Valproic Acid 48-61 histone deacetylase 9 Homo sapiens 33-37 26108793-9 2015 When oocytes were exposed to the HDAC inhibitor valproic acid, results indicated that HDAC regulated transcriptional activity in the nucleoplasm, but not in the nucleolus. Valproic Acid 48-61 histone deacetylase 9 Homo sapiens 86-90 26318673-3 2015 Here, we showed that histone deacetylase (HDAC) inhibitors, such as trichostatin A and valproic acid, restored peripheral and systemic morphine analgesia in neuropathic pain. Valproic Acid 87-100 histone deacetylase 9 Homo sapiens 42-46 26735433-2 2015 The HDAC (histone deacetylase) inhibitor valproic acid (VPA) interacted synergistically with chemotherapeutic agents to trigger lymphoma cell autophagy, which resulted from activation of AMPK (AMP-activated protein kinase) and inhibition of downstream MTOR (mechanistic target of rapamycin [serine/threonine kinase]) signaling. Valproic Acid 41-54 histone deacetylase 9 Homo sapiens 4-8 25960665-4 2015 One HDAC inhibitor, valproic acid (VPA), also inhibits tumor growth by inducing apoptosis, and enhances the efficacy of paclitaxel in a mouse xenograft model of gastric cancer. Valproic Acid 20-33 histone deacetylase 9 Homo sapiens 4-8 25960665-4 2015 One HDAC inhibitor, valproic acid (VPA), also inhibits tumor growth by inducing apoptosis, and enhances the efficacy of paclitaxel in a mouse xenograft model of gastric cancer. Valproic Acid 35-38 histone deacetylase 9 Homo sapiens 4-8 25656984-1 2015 PURPOSE: Valproic acid is an anticonvulsant that also inhibits histone deacetylase (HDAC), a property that could worsen pulmonary function in patients with chronic obstructive pulmonary disease (COPD). Valproic Acid 9-22 histone deacetylase 9 Homo sapiens 63-82 25656984-1 2015 PURPOSE: Valproic acid is an anticonvulsant that also inhibits histone deacetylase (HDAC), a property that could worsen pulmonary function in patients with chronic obstructive pulmonary disease (COPD). Valproic Acid 9-22 histone deacetylase 9 Homo sapiens 84-88 25656984-11 2015 These findings suggest that valproate-induced HDAC inhibition is of little clinical relevance in this context. Valproic Acid 28-37 histone deacetylase 9 Homo sapiens 46-50 26185616-9 2015 Valproic acid, a HDAC inhibitor, suppressed the growth of AR/cPAcP-positive PCa cells by over 50% in steroid-reduced conditions, higher than on AR/cPAcP-negative PCa cells. Valproic Acid 0-13 histone deacetylase 9 Homo sapiens 17-21 25950486-2 2015 The aim of this study was to identify potential developmental toxicity mechanisms of the histone deacetylase inhibitors (HDAC) valproic acid (VPA), suberoylanilide hydroxamic acid (SAHA) and trichostatin A (TSA) relevant to the in vivo condition using a hESC model in combination with specific differentiation protocols and genome-wide gene expression and microRNA profiling. Valproic Acid 127-140 histone deacetylase 9 Homo sapiens 89-119 25950486-2 2015 The aim of this study was to identify potential developmental toxicity mechanisms of the histone deacetylase inhibitors (HDAC) valproic acid (VPA), suberoylanilide hydroxamic acid (SAHA) and trichostatin A (TSA) relevant to the in vivo condition using a hESC model in combination with specific differentiation protocols and genome-wide gene expression and microRNA profiling. Valproic Acid 127-140 histone deacetylase 9 Homo sapiens 121-125 25950486-2 2015 The aim of this study was to identify potential developmental toxicity mechanisms of the histone deacetylase inhibitors (HDAC) valproic acid (VPA), suberoylanilide hydroxamic acid (SAHA) and trichostatin A (TSA) relevant to the in vivo condition using a hESC model in combination with specific differentiation protocols and genome-wide gene expression and microRNA profiling. Valproic Acid 142-145 histone deacetylase 9 Homo sapiens 89-119 25950486-2 2015 The aim of this study was to identify potential developmental toxicity mechanisms of the histone deacetylase inhibitors (HDAC) valproic acid (VPA), suberoylanilide hydroxamic acid (SAHA) and trichostatin A (TSA) relevant to the in vivo condition using a hESC model in combination with specific differentiation protocols and genome-wide gene expression and microRNA profiling. Valproic Acid 142-145 histone deacetylase 9 Homo sapiens 121-125 25336333-3 2015 METHODS: The objective of this study was to evaluate the possible benefit of adding valproic acid, an HDAC inhibitor, to decitabine in the treatment of MDS and AML. Valproic Acid 84-97 histone deacetylase 9 Homo sapiens 102-106 26735433-0 2015 Induction of autophagy by valproic acid enhanced lymphoma cell chemosensitivity through HDAC-independent and IP3-mediated PRKAA activation. Valproic Acid 26-39 histone deacetylase 9 Homo sapiens 88-92 26735433-2 2015 The HDAC (histone deacetylase) inhibitor valproic acid (VPA) interacted synergistically with chemotherapeutic agents to trigger lymphoma cell autophagy, which resulted from activation of AMPK (AMP-activated protein kinase) and inhibition of downstream MTOR (mechanistic target of rapamycin [serine/threonine kinase]) signaling. Valproic Acid 41-54 histone deacetylase 9 Homo sapiens 10-29 26735433-2 2015 The HDAC (histone deacetylase) inhibitor valproic acid (VPA) interacted synergistically with chemotherapeutic agents to trigger lymphoma cell autophagy, which resulted from activation of AMPK (AMP-activated protein kinase) and inhibition of downstream MTOR (mechanistic target of rapamycin [serine/threonine kinase]) signaling. Valproic Acid 56-59 histone deacetylase 9 Homo sapiens 4-8 26735433-2 2015 The HDAC (histone deacetylase) inhibitor valproic acid (VPA) interacted synergistically with chemotherapeutic agents to trigger lymphoma cell autophagy, which resulted from activation of AMPK (AMP-activated protein kinase) and inhibition of downstream MTOR (mechanistic target of rapamycin [serine/threonine kinase]) signaling. Valproic Acid 56-59 histone deacetylase 9 Homo sapiens 10-29 25108044-0 2014 The histone deacetylase (HDAC) inhibitor valproic acid reduces ethanol consumption and ethanol-conditioned place preference in rats. Valproic Acid 41-54 histone deacetylase 9 Homo sapiens 25-29 25012937-0 2015 HDAC inhibition through valproic acid modulates the methylation profiles in human embryonic kidney cells. Valproic Acid 24-37 histone deacetylase 9 Homo sapiens 0-4 25012937-4 2015 Valproic acid (VPA), belonging to the short-chain fatty acid group of HDAC inhibitors, modulates the epigenome altering gene expression profiles across cell lines. Valproic Acid 0-13 histone deacetylase 9 Homo sapiens 70-74 25012937-4 2015 Valproic acid (VPA), belonging to the short-chain fatty acid group of HDAC inhibitors, modulates the epigenome altering gene expression profiles across cell lines. Valproic Acid 15-18 histone deacetylase 9 Homo sapiens 70-74 25446377-7 2014 Histone deacetylase (HDAC) inhibitor valproic acid (VPA) increased expression of BNIP3 in Raji cells at perinuclear locations. Valproic Acid 37-50 histone deacetylase 9 Homo sapiens 0-19 25446377-7 2014 Histone deacetylase (HDAC) inhibitor valproic acid (VPA) increased expression of BNIP3 in Raji cells at perinuclear locations. Valproic Acid 37-50 histone deacetylase 9 Homo sapiens 21-25 25446377-7 2014 Histone deacetylase (HDAC) inhibitor valproic acid (VPA) increased expression of BNIP3 in Raji cells at perinuclear locations. Valproic Acid 52-55 histone deacetylase 9 Homo sapiens 0-19 25446377-7 2014 Histone deacetylase (HDAC) inhibitor valproic acid (VPA) increased expression of BNIP3 in Raji cells at perinuclear locations. Valproic Acid 52-55 histone deacetylase 9 Homo sapiens 21-25 25108044-3 2014 In the current study, we studied the effects of systemic injection of the histone deacetylase (HDAC) inhibitor, valproic acid (VPA) on ethanol consumption and ethanol-elicited conditioned place preference (CPP). Valproic Acid 112-125 histone deacetylase 9 Homo sapiens 95-99 25108044-3 2014 In the current study, we studied the effects of systemic injection of the histone deacetylase (HDAC) inhibitor, valproic acid (VPA) on ethanol consumption and ethanol-elicited conditioned place preference (CPP). Valproic Acid 127-130 histone deacetylase 9 Homo sapiens 95-99 23647222-0 2013 The mood stabilizer valproate activates human FGF1 gene promoter through inhibiting HDAC and GSK-3 activities. Valproic Acid 20-29 histone deacetylase 9 Homo sapiens 84-88 24511897-1 2014 VPA (valproic acid), a short-chain fatty acid that is a HDAC (histone deacetylase) inhibitor, is known to suppress adipogenesis. Valproic Acid 0-3 histone deacetylase 9 Homo sapiens 56-60 24511897-1 2014 VPA (valproic acid), a short-chain fatty acid that is a HDAC (histone deacetylase) inhibitor, is known to suppress adipogenesis. Valproic Acid 0-3 histone deacetylase 9 Homo sapiens 62-81 24511897-1 2014 VPA (valproic acid), a short-chain fatty acid that is a HDAC (histone deacetylase) inhibitor, is known to suppress adipogenesis. Valproic Acid 5-18 histone deacetylase 9 Homo sapiens 56-60 24511897-1 2014 VPA (valproic acid), a short-chain fatty acid that is a HDAC (histone deacetylase) inhibitor, is known to suppress adipogenesis. Valproic Acid 5-18 histone deacetylase 9 Homo sapiens 62-81 24006305-1 2013 The influence of the histone deacetylase (HDAC)-inhibitor, valproic acid (VPA), on bladder cancer cell adhesion in vitro was investigated in this paper. Valproic Acid 59-72 histone deacetylase 9 Homo sapiens 21-40 24006305-1 2013 The influence of the histone deacetylase (HDAC)-inhibitor, valproic acid (VPA), on bladder cancer cell adhesion in vitro was investigated in this paper. Valproic Acid 59-72 histone deacetylase 9 Homo sapiens 42-46 24006305-1 2013 The influence of the histone deacetylase (HDAC)-inhibitor, valproic acid (VPA), on bladder cancer cell adhesion in vitro was investigated in this paper. Valproic Acid 74-77 histone deacetylase 9 Homo sapiens 21-40 24006305-1 2013 The influence of the histone deacetylase (HDAC)-inhibitor, valproic acid (VPA), on bladder cancer cell adhesion in vitro was investigated in this paper. Valproic Acid 74-77 histone deacetylase 9 Homo sapiens 42-46 24890032-0 2014 Is sodium valproate, an HDAC inhibitor, associated with reduced risk of stroke and myocardial infarction? Valproic Acid 3-19 histone deacetylase 9 Homo sapiens 24-28 23010695-1 2013 The aim of this study was to identify valproic acid (VPA) analogs with a broad spectrum of anti-cancer activities and an increased apoptosis-inducing potential compared with the parent VPA, which is enrolled as histone deacetylase (HDAC) inhibitor in a large number of clinical trials. Valproic Acid 38-51 histone deacetylase 9 Homo sapiens 211-230 23097134-1 2013 Sodium valproate (VPA) has been recently identified as a selective class I histone deacetylase (HDAC) inhibitor and explored for its potential as an anti-cancer agent. Valproic Acid 0-16 histone deacetylase 9 Homo sapiens 96-100 23097134-1 2013 Sodium valproate (VPA) has been recently identified as a selective class I histone deacetylase (HDAC) inhibitor and explored for its potential as an anti-cancer agent. Valproic Acid 18-21 histone deacetylase 9 Homo sapiens 96-100 23836985-0 2013 Inhibition of leukemic cells by valproic acid, an HDAC inhibitor, in xenograft tumors. Valproic Acid 32-45 histone deacetylase 9 Homo sapiens 50-54 23010695-1 2013 The aim of this study was to identify valproic acid (VPA) analogs with a broad spectrum of anti-cancer activities and an increased apoptosis-inducing potential compared with the parent VPA, which is enrolled as histone deacetylase (HDAC) inhibitor in a large number of clinical trials. Valproic Acid 38-51 histone deacetylase 9 Homo sapiens 232-236 23010695-1 2013 The aim of this study was to identify valproic acid (VPA) analogs with a broad spectrum of anti-cancer activities and an increased apoptosis-inducing potential compared with the parent VPA, which is enrolled as histone deacetylase (HDAC) inhibitor in a large number of clinical trials. Valproic Acid 53-56 histone deacetylase 9 Homo sapiens 211-230 23010695-1 2013 The aim of this study was to identify valproic acid (VPA) analogs with a broad spectrum of anti-cancer activities and an increased apoptosis-inducing potential compared with the parent VPA, which is enrolled as histone deacetylase (HDAC) inhibitor in a large number of clinical trials. Valproic Acid 53-56 histone deacetylase 9 Homo sapiens 232-236 23292124-1 2013 The aim of this study was to elucidate whether the treatment of a prostate carcinoma cell line (LNCaP) and LNCaP-derived tumors with the histone deacetylase (HDAC) inhibitor valproate in combination with the mammalian target of rapamycin (mTOR) inhibitor temsirolimus resulted in synergistic effects on cell proliferation and tumor growth. Valproic Acid 174-183 histone deacetylase 9 Homo sapiens 137-156 23292124-1 2013 The aim of this study was to elucidate whether the treatment of a prostate carcinoma cell line (LNCaP) and LNCaP-derived tumors with the histone deacetylase (HDAC) inhibitor valproate in combination with the mammalian target of rapamycin (mTOR) inhibitor temsirolimus resulted in synergistic effects on cell proliferation and tumor growth. Valproic Acid 174-183 histone deacetylase 9 Homo sapiens 158-162 23448466-6 2013 Specifically, HDAC inhibitors such as trichostatin A, valproic acid, sodium butyrate, sodium 4-phenylbutyrate, and suberoylanilide hydroxamic acid have been shown to provide robust protection against excitotoxicity, oxidative stress, ER stress, apoptosis, inflammation, and bloodbrain barrier breakdown. Valproic Acid 54-67 histone deacetylase 9 Homo sapiens 14-18 22473339-1 2012 We evaluated whether low-dosed interferon alpha (IFNa) may augment the anti-tumor potential of the histone deacetylase (HDAC)-inhibitor valproic acid (VPA) on prostate cancer cells in vitro and in vivo. Valproic Acid 136-149 histone deacetylase 9 Homo sapiens 99-118 22473339-1 2012 We evaluated whether low-dosed interferon alpha (IFNa) may augment the anti-tumor potential of the histone deacetylase (HDAC)-inhibitor valproic acid (VPA) on prostate cancer cells in vitro and in vivo. Valproic Acid 136-149 histone deacetylase 9 Homo sapiens 120-124 22473339-1 2012 We evaluated whether low-dosed interferon alpha (IFNa) may augment the anti-tumor potential of the histone deacetylase (HDAC)-inhibitor valproic acid (VPA) on prostate cancer cells in vitro and in vivo. Valproic Acid 151-154 histone deacetylase 9 Homo sapiens 99-118 22473339-1 2012 We evaluated whether low-dosed interferon alpha (IFNa) may augment the anti-tumor potential of the histone deacetylase (HDAC)-inhibitor valproic acid (VPA) on prostate cancer cells in vitro and in vivo. Valproic Acid 151-154 histone deacetylase 9 Homo sapiens 120-124 22863973-2 2012 Previously, we have shown that valproic acid (VPA), a histone deacetylase (HDAC) inhibitor, exerts antitumor effects in an NB xenograft model. Valproic Acid 31-44 histone deacetylase 9 Homo sapiens 54-73 22863973-2 2012 Previously, we have shown that valproic acid (VPA), a histone deacetylase (HDAC) inhibitor, exerts antitumor effects in an NB xenograft model. Valproic Acid 31-44 histone deacetylase 9 Homo sapiens 75-79 22863973-2 2012 Previously, we have shown that valproic acid (VPA), a histone deacetylase (HDAC) inhibitor, exerts antitumor effects in an NB xenograft model. Valproic Acid 46-49 histone deacetylase 9 Homo sapiens 54-73 22863973-2 2012 Previously, we have shown that valproic acid (VPA), a histone deacetylase (HDAC) inhibitor, exerts antitumor effects in an NB xenograft model. Valproic Acid 46-49 histone deacetylase 9 Homo sapiens 75-79 22961641-2 2012 Valproic acid (VA) is a histone deacetylase (HDAC) inhibitor that promotes self-renewal and expansion of hematopoietic stem cells and facilitates the generation of induced pluripotent stem cells from somatic cells and is currently being investigated in breast cancer clinical trials. Valproic Acid 0-13 histone deacetylase 9 Homo sapiens 24-43 22961641-2 2012 Valproic acid (VA) is a histone deacetylase (HDAC) inhibitor that promotes self-renewal and expansion of hematopoietic stem cells and facilitates the generation of induced pluripotent stem cells from somatic cells and is currently being investigated in breast cancer clinical trials. Valproic Acid 0-13 histone deacetylase 9 Homo sapiens 45-49 22961641-2 2012 Valproic acid (VA) is a histone deacetylase (HDAC) inhibitor that promotes self-renewal and expansion of hematopoietic stem cells and facilitates the generation of induced pluripotent stem cells from somatic cells and is currently being investigated in breast cancer clinical trials. Valproic Acid 15-17 histone deacetylase 9 Homo sapiens 24-43 22961641-2 2012 Valproic acid (VA) is a histone deacetylase (HDAC) inhibitor that promotes self-renewal and expansion of hematopoietic stem cells and facilitates the generation of induced pluripotent stem cells from somatic cells and is currently being investigated in breast cancer clinical trials. Valproic Acid 15-17 histone deacetylase 9 Homo sapiens 45-49 21556798-2 2011 METHODS: We investigated the anticancer effects of the HDAC inhibitor valproic acid (VPA) in combination with gemcitabine (GEM), an antimetabolic, and pegylated interferon-alpha2b (PEG-IFN-alpha2b) in a human pancreatic cancer cell line using a cell proliferation assay. Valproic Acid 70-83 histone deacetylase 9 Homo sapiens 55-59 22953987-1 2012 Platinum(IV) prodrug diaminedichlorodihydroxyplatinum (ACHP) conjugated with a histone deacetylase (HDAC) inhibitor valproic acid (VA), VAAP, exhibited strong synergistic cytotoxicity, about 50-100 times more cytotoxic than ACHP or its simple mixture with VA, against various human carcinoma cell lines. Valproic Acid 116-129 histone deacetylase 9 Homo sapiens 79-98 22953987-1 2012 Platinum(IV) prodrug diaminedichlorodihydroxyplatinum (ACHP) conjugated with a histone deacetylase (HDAC) inhibitor valproic acid (VA), VAAP, exhibited strong synergistic cytotoxicity, about 50-100 times more cytotoxic than ACHP or its simple mixture with VA, against various human carcinoma cell lines. Valproic Acid 116-129 histone deacetylase 9 Homo sapiens 100-104 22953987-1 2012 Platinum(IV) prodrug diaminedichlorodihydroxyplatinum (ACHP) conjugated with a histone deacetylase (HDAC) inhibitor valproic acid (VA), VAAP, exhibited strong synergistic cytotoxicity, about 50-100 times more cytotoxic than ACHP or its simple mixture with VA, against various human carcinoma cell lines. Valproic Acid 131-133 histone deacetylase 9 Homo sapiens 79-98 22953987-1 2012 Platinum(IV) prodrug diaminedichlorodihydroxyplatinum (ACHP) conjugated with a histone deacetylase (HDAC) inhibitor valproic acid (VA), VAAP, exhibited strong synergistic cytotoxicity, about 50-100 times more cytotoxic than ACHP or its simple mixture with VA, against various human carcinoma cell lines. Valproic Acid 131-133 histone deacetylase 9 Homo sapiens 100-104 22953987-1 2012 Platinum(IV) prodrug diaminedichlorodihydroxyplatinum (ACHP) conjugated with a histone deacetylase (HDAC) inhibitor valproic acid (VA), VAAP, exhibited strong synergistic cytotoxicity, about 50-100 times more cytotoxic than ACHP or its simple mixture with VA, against various human carcinoma cell lines. Valproic Acid 136-138 histone deacetylase 9 Homo sapiens 79-98 22953987-1 2012 Platinum(IV) prodrug diaminedichlorodihydroxyplatinum (ACHP) conjugated with a histone deacetylase (HDAC) inhibitor valproic acid (VA), VAAP, exhibited strong synergistic cytotoxicity, about 50-100 times more cytotoxic than ACHP or its simple mixture with VA, against various human carcinoma cell lines. Valproic Acid 136-138 histone deacetylase 9 Homo sapiens 100-104 22701306-7 2012 The connectivity map analysis showed gene expression profile in K562 cells exposed to sodium valproate was most similar to that of HDACi and PI3K inhibitors, suggesting that sodium valproate might exert antileukaemic action by inhibiting HDAC as well as inhibiting PI3K pathway. Valproic Acid 174-190 histone deacetylase 9 Homo sapiens 131-135 21556798-2 2011 METHODS: We investigated the anticancer effects of the HDAC inhibitor valproic acid (VPA) in combination with gemcitabine (GEM), an antimetabolic, and pegylated interferon-alpha2b (PEG-IFN-alpha2b) in a human pancreatic cancer cell line using a cell proliferation assay. Valproic Acid 85-88 histone deacetylase 9 Homo sapiens 55-59 21838863-4 2011 Here, we show that the HDAC inhibitors valproic acid (VPA) and trichostatin A (TSA) are unable to reactivate HIV in latently infected primary CD4 T cells generated in the H80 co-culture system. Valproic Acid 39-52 histone deacetylase 9 Homo sapiens 23-27 21805043-2 2011 Valproic acid (VPA) is one of the clinically available HDAC inhibitors. Valproic Acid 0-13 histone deacetylase 9 Homo sapiens 55-59 21805043-2 2011 Valproic acid (VPA) is one of the clinically available HDAC inhibitors. Valproic Acid 15-18 histone deacetylase 9 Homo sapiens 55-59 21771726-5 2011 Among all studied HDAC inhibitors, valproic acid (VPA) and CI-994 showed prolonged effects on histone acetylation, while combination with decitabine produced the most prominent effects on caspase-8 re-expression. Valproic Acid 35-48 histone deacetylase 9 Homo sapiens 18-22 21771726-5 2011 Among all studied HDAC inhibitors, valproic acid (VPA) and CI-994 showed prolonged effects on histone acetylation, while combination with decitabine produced the most prominent effects on caspase-8 re-expression. Valproic Acid 50-53 histone deacetylase 9 Homo sapiens 18-22 21336812-3 2011 Clinically, valproic acid fetopathy sheds some insight into the effects of altered HDACs on human embryonic development, since valproic acid is an antiepileptic drug and an HDAC inhibitor. Valproic Acid 12-25 histone deacetylase 9 Homo sapiens 83-87 21336812-3 2011 Clinically, valproic acid fetopathy sheds some insight into the effects of altered HDACs on human embryonic development, since valproic acid is an antiepileptic drug and an HDAC inhibitor. Valproic Acid 127-140 histone deacetylase 9 Homo sapiens 83-87 21838863-4 2011 Here, we show that the HDAC inhibitors valproic acid (VPA) and trichostatin A (TSA) are unable to reactivate HIV in latently infected primary CD4 T cells generated in the H80 co-culture system. Valproic Acid 54-57 histone deacetylase 9 Homo sapiens 23-27 21411522-0 2011 Valproic acid antagonizes the capacity of other histone deacetylase inhibitors to activate the Epstein-barr virus lytic cycle. Valproic Acid 0-13 histone deacetylase 9 Homo sapiens 48-67 21411522-3 2011 Valproic acid (VPA), which, like NaB, belongs to the short-chain fatty acid class of HDAC inhibitors, fails to induce the EBV lytic cycle in these cells. Valproic Acid 0-13 histone deacetylase 9 Homo sapiens 85-89 21411522-3 2011 Valproic acid (VPA), which, like NaB, belongs to the short-chain fatty acid class of HDAC inhibitors, fails to induce the EBV lytic cycle in these cells. Valproic Acid 15-18 histone deacetylase 9 Homo sapiens 85-89 21411522-4 2011 Nonetheless, VPA behaves as an HDAC inhibitor; it causes hyperacetylation of histone H3 (J. K. Countryman, L. Gradoville, and G. Miller, J. Virol. Valproic Acid 13-16 histone deacetylase 9 Homo sapiens 31-35 20451370-6 2010 As expected for an HDAC inhibitor, VPA hyperacetylates histone H3. Valproic Acid 35-38 histone deacetylase 9 Homo sapiens 19-23 21193210-7 2011 CONCLUSION: The HDAC inhibitors TSA and VA decreased the protein activity of MMP-2 and MMP-9 and, in combination with the demethylating agent 5-AZC, inhibited cellular growth in human papillary and follicular thyroid cancer cell lines. Valproic Acid 40-42 histone deacetylase 9 Homo sapiens 16-20 21789227-6 2011 In the present study cord blood-derived CD34(+) were pre-conditioned with the HDAC inhibitor Valproic Acid. Valproic Acid 93-106 histone deacetylase 9 Homo sapiens 78-82 21429295-3 2011 The HDAC inhibitors trichostatin A, suberoylanilide hydroxamic acid, sodium butyrate, and valproic acid induced early differentiation of mouse ES cells and triggered induction of heatshock protein (HSP)70. Valproic Acid 90-103 histone deacetylase 9 Homo sapiens 4-8 21192952-0 2011 Inhibitory effects of the HDAC inhibitor valproic acid on prostate cancer growth are enhanced by simultaneous application of the mTOR inhibitor RAD001. Valproic Acid 41-54 histone deacetylase 9 Homo sapiens 26-30 21192952-1 2011 AIMS: To analyze the combined impact of the histone deacetylase (HDAC) inhibitor valproic acid (VPA) and the mammalian target of rapamycin (mTOR) inhibitor RAD001 on prostate cancer cell growth. Valproic Acid 81-94 histone deacetylase 9 Homo sapiens 65-69 21192952-1 2011 AIMS: To analyze the combined impact of the histone deacetylase (HDAC) inhibitor valproic acid (VPA) and the mammalian target of rapamycin (mTOR) inhibitor RAD001 on prostate cancer cell growth. Valproic Acid 96-99 histone deacetylase 9 Homo sapiens 65-69 21966390-0 2011 Effects of the histone deacetylase inhibitor valproic acid on human pericytes in vitro. Valproic Acid 45-58 histone deacetylase 9 Homo sapiens 15-34 21966390-3 2011 The present study investigates the effects of the histone deacetylase (HDAC) inhibitor valproic acid (VPA) on pericyte proliferation, cell viability, migration and differentiation. Valproic Acid 87-100 histone deacetylase 9 Homo sapiens 50-69 21966390-3 2011 The present study investigates the effects of the histone deacetylase (HDAC) inhibitor valproic acid (VPA) on pericyte proliferation, cell viability, migration and differentiation. Valproic Acid 87-100 histone deacetylase 9 Homo sapiens 71-75 21966390-3 2011 The present study investigates the effects of the histone deacetylase (HDAC) inhibitor valproic acid (VPA) on pericyte proliferation, cell viability, migration and differentiation. Valproic Acid 102-105 histone deacetylase 9 Homo sapiens 50-69 21966390-3 2011 The present study investigates the effects of the histone deacetylase (HDAC) inhibitor valproic acid (VPA) on pericyte proliferation, cell viability, migration and differentiation. Valproic Acid 102-105 histone deacetylase 9 Homo sapiens 71-75 20451370-3 2010 The goal of this study was to evaluate the anticancer efficacy of a HDAC inhibitor (valproate: VPA) on SCLC cells in combination with the standard chemotherapeutic first-line regimen (cisplatin+etoposide). Valproic Acid 84-93 histone deacetylase 9 Homo sapiens 68-72 20451370-3 2010 The goal of this study was to evaluate the anticancer efficacy of a HDAC inhibitor (valproate: VPA) on SCLC cells in combination with the standard chemotherapeutic first-line regimen (cisplatin+etoposide). Valproic Acid 95-98 histone deacetylase 9 Homo sapiens 68-72 20339522-3 2010 Here we report a mycosis fungoides patient having a dramatic response to hydralazine and valproate, two repositioned drugs as HDAC and DNA methylation inhibitors, respectively. Valproic Acid 89-98 histone deacetylase 9 Homo sapiens 126-130 20096088-2 2010 We demonstrated that inhibition of histone deacetylase activity by trichostatin A (TSA), valproic acid and sodium butyrate caused a potent induction of both CYP46A1 promoter activity and endogenous expression. Valproic Acid 89-102 histone deacetylase 9 Homo sapiens 35-54 19681894-1 2010 OBJECTIVE: To examine the expression profile of histone deacetylase (HDAC)-1 and explore its potential role in the development of bladder cancer, using valproic acid (VPA), a HDAC inhibitor, which reduces tumour growth and metastasis formation in animal models. Valproic Acid 152-165 histone deacetylase 9 Homo sapiens 69-73 19681894-1 2010 OBJECTIVE: To examine the expression profile of histone deacetylase (HDAC)-1 and explore its potential role in the development of bladder cancer, using valproic acid (VPA), a HDAC inhibitor, which reduces tumour growth and metastasis formation in animal models. Valproic Acid 167-170 histone deacetylase 9 Homo sapiens 69-73 19322073-1 2009 Histone deacetylase (HDAC) inhibitors such as vorinostat (suberoylanilide hydroxamic acid), valproic acid, romidepsin (FK-228), and LBH589 comprise a relatively new class of potent anticancer agents. Valproic Acid 92-105 histone deacetylase 9 Homo sapiens 0-19 19322073-4 2009 This acquired resistance also associates with cross-resistance to the hydroxamate-class (LBH589 and JNJ26481585) and to the aliphatic acid-class (valproic acid) HDAC inhibitors but not to the benzamide-class (MGCD0103) and the cyclic peptide-class (romidepsin) HDAC inhibitors. Valproic Acid 146-159 histone deacetylase 9 Homo sapiens 161-165 19379567-1 2009 This study was aimed to investigate the mechanism of histone deacetylase (HDAC) inhibitor, valproic acid (VPA), reversing transcription inhibition of AML1-ETO fusion protein in Kasumi-1 cell line. Valproic Acid 91-104 histone deacetylase 9 Homo sapiens 53-72 19318486-0 2009 Clinical and biological effects of valproic acid as a histone deacetylase inhibitor on tumor and surrogate tissues: phase I/II trial of valproic acid and epirubicin/FEC. Valproic Acid 35-48 histone deacetylase 9 Homo sapiens 54-73 19318486-1 2009 PURPOSE: The aim was to study the biological and molecular effects of the histone deacetylase (HDAC) inhibitor, valproic acid, in patients with solid tumor malignancies. Valproic Acid 112-125 histone deacetylase 9 Homo sapiens 74-93 19318486-1 2009 PURPOSE: The aim was to study the biological and molecular effects of the histone deacetylase (HDAC) inhibitor, valproic acid, in patients with solid tumor malignancies. Valproic Acid 112-125 histone deacetylase 9 Homo sapiens 95-99 19318486-10 2009 CONCLUSION: Valproic acid is a clinically relevant HDAC inhibitor, and PBMCs may serve as a surrogate for tumor histone acetylation in solid tumor malignancies. Valproic Acid 12-25 histone deacetylase 9 Homo sapiens 51-55 19379567-1 2009 This study was aimed to investigate the mechanism of histone deacetylase (HDAC) inhibitor, valproic acid (VPA), reversing transcription inhibition of AML1-ETO fusion protein in Kasumi-1 cell line. Valproic Acid 91-104 histone deacetylase 9 Homo sapiens 74-78 19379567-1 2009 This study was aimed to investigate the mechanism of histone deacetylase (HDAC) inhibitor, valproic acid (VPA), reversing transcription inhibition of AML1-ETO fusion protein in Kasumi-1 cell line. Valproic Acid 106-109 histone deacetylase 9 Homo sapiens 53-72 19379567-1 2009 This study was aimed to investigate the mechanism of histone deacetylase (HDAC) inhibitor, valproic acid (VPA), reversing transcription inhibition of AML1-ETO fusion protein in Kasumi-1 cell line. Valproic Acid 106-109 histone deacetylase 9 Homo sapiens 74-78 19190121-4 2009 Treatment of FTC236 cells with HDAC inhibitors valproic acid (1-4 mmol/L) or suberoyl bishydroxamic acid (10-30 micromol/L) induced functional Notch1 protein expression and suppressed cell growth in a dose-dependent manner. Valproic Acid 47-60 histone deacetylase 9 Homo sapiens 31-35